Aptose Biosciences (LTI0) Price & Analysis

Compare

1 Followers

LTI0 Stock Chart & Stats

€1.18

Market closed

€1.18

Day’s Range― - ―

52-Week Range€0.66 - €10.86

Previous CloseN/A

VolumeN/A

Average Volume (3M)0.00

Market Cap

$3.15M

Enterprise Value€16.69M

Total Cash (Recent Filing)$553.00K

Total Debt (Recent Filing)$11.38M

Price to Earnings (P/E)―

Beta0.17

Next Earnings

Mar 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding2,552,429

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)-34.40

Price to Sales (P/S)0.00

P/FCF Ratio-4.34

Enterprise Value/Market Cap5.30

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.83

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentTuspetinib is a highly differentiated kinase inhibitor with favorable safety and broad activity across difficult-to-treat AML subpopulations, including those with TP53, RAS, and FLT3 mutations.

Clinical Study ResultsTUSCANY exhibits initial signs of promise in newly diagnosed AML, with initial safety and efficacy data showing favorable outcomes.

Financial PositionThe company ended the year with $6.7 million in cash, which management believes should provide runway for ongoing operations through April 2025.

Bears Say

Funding NeedsAptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement to provide necessary additional funding and accelerate clinical development of tuspetinib.

Aptose Biosciences News

Aptose Biosciences’ TUSCANY Study Highlighted at ASH 2025

Aptose Biosciences ( ($TSE:APS) ) just unveiled an update. On November 3, 2025, Aptose Biosciences announced that an...

7d ago

Aptose Biosciences’ Tuspetinib Study: A Potential Game-Changer in Leukemia Treatment

Aptose Biosciences Inc. (($APTOF)) announced an update on their ongoing clinical study. Aptose Biosciences Inc. is conducting a...

13d ago

APTOF

Aptose’s Tuspetinib Shows Promising Results in AML Treatment Trial

Aptose Biosciences ( ($TSE:APS) ) has issued an announcement. Aptose Biosciences announced promising results from its Phase 1/2...

25d ago

Aptose Secures $11.9M Loan for AML Therapy Development

The latest update is out from Aptose Biosciences ( ($TSE:APS) ). Aptose Biosciences has extended a loan agreement...

2M ago

Aptose Biosciences Announces Executive Retention Awards

Aptose Biosciences ( ($TSE:APS) ) just unveiled an announcement. On August 19, 2025, Aptose Biosciences Inc announced retention...

2M ago

Aptose Biosciences Secures Funding for Drug Development

Aptose Biosciences ( ($TSE:APS) ) has issued an update. On August 22, 2025, Aptose Biosciences held its reconvened...

3M ago

Aptose Biosciences Appoints New Independent Auditor

The latest announcement is out from Aptose Biosciences ( ($TSE:APS) ). On August 22, 2025, Aptose Biosciences announced...

3M ago

Aptose Biosciences Reports Positive Early Data from TUSCANY Trial for AML Treatment

Aptose Biosciences ( ($TSE:APS) ) has shared an announcement. Aptose Biosciences has reported promising early data from its...

3M ago

Aptose Biosciences Reports Promising Q2 2025 Results

Aptose Biosciences ( ($APTOF) ) has released its Q2 earnings. Here is a breakdown of the information Aptose...

3M ago

Aptose Biosciences Advances Tuspetinib in AML Treatment with Promising Trial Results

The latest update is out from Aptose Biosciences ( ($TSE:APS) ). Aptose Biosciences announced its second quarter 2025...

3M ago

Aptose Biosciences shares to delist from Nasdaq as of April 2

Aptose Biosciences (APTO) announced that the Nasdaq Hearings Panel has determined to delist the common shares of the...

7M ago

APTO

Aptose Biosciences price target raised to $6 from $2 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2...

8M ago

APTO

Aptose Biosciences reports FY24 EPS ($36.38) vs. ($227.43) last year

“During 2024 and into 2025, we continue to advance our lead investigational drug tuspetinib in combination with venetoclax...

8M ago

APTO

Aptose Biosciences meets Nasdaq minimum bid price compliance

Aptose Biosciences (APTO) received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market notifying...

8M ago

APTO

LTI0 FAQ

What was Aptose Biosciences’s price range in the past 12 months?

Aptose Biosciences lowest stock price was €0.66 and its highest was €10.86 in the past 12 months.

What is Aptose Biosciences’s market cap?

Aptose Biosciences’s market cap is $3.15M.

When is Aptose Biosciences’s upcoming earnings report date?

Aptose Biosciences’s upcoming earnings report date is Mar 24, 2026 which is in 134 days.

How were Aptose Biosciences’s earnings last quarter?

Currently, no data Available

Is Aptose Biosciences overvalued?

According to Wall Street analysts Aptose Biosciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Aptose Biosciences pay dividends?

Aptose Biosciences does not currently pay dividends.

What is Aptose Biosciences’s EPS estimate?

Aptose Biosciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aptose Biosciences have?

Aptose Biosciences has 2,552,429 shares outstanding.

What happened to Aptose Biosciences’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Aptose Biosciences?

Currently, no hedge funds are holding shares in DE:LTI0

Company Description

Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.